Earnings Release • Aug 7, 2015
Earnings Release
Open in ViewerOpens in native device viewer
News Details
Corporate | 7 August 2015 07:00
Carl Zeiss Meditec AG benefits from currency effects
Carl Zeiss Meditec AG / Key word(s): 9-month figures
2015-08-07 / 07:00
| Carl Zeiss Meditec AG benefits from currency effects |
| Revenue increases to EUR 748.7 million / higher expenses for upfront R&D investment impact result slightly |
JENA, 7 August 2015
Aided by positive currency effects, medical technology company Carl Zeiss Meditec AG increased its revenue by 11.1 percent in the first nine months of financial year 2014/15, to EUR 748.7 million (previous year: EUR 673.7 million); after adjustment for currency effects, this corresponds to growth of 5.4 percent. At EUR 89.5 million, EBIT was once again lower in this quarter compared with the previous year (EUR 92.1 million), due to higher R&D expenses; on an adjusted basis, however, an increase of 5.8%, to EUR 99.5 million, would have been recorded. Earnings per share were 9 percent lower than the previous year, amounting to EUR 0.64. Effects at the end of the reporting period, arising from the valuation of currency hedging transactions, continued to have an adverse effect in this respect. The effect was, however, less significant after nine months than at the six-month point in 2014/15.
“Boosted by the exchange rates for key currencies, we further increased our revenue after nine months of 2014/15. Our growth comes from all business areas and regions,” says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.
Key figures by business unit at a glance
The strongest growth rate was once again achieved by the strategic business unit (SBU) Surgical Ophthalmology, which increased its revenue by 17.3 percent (adjusted for currency effects, 14.2 percent), to EUR 258.5 million (previous year: EUR 220.3 million). Revenue of the Ophthalmic Systems SBU increased by 13.9 percent (adjusted for currency effects, 5.7 percent), to EUR 283.5 million (previous year: EUR 248.9 million).
The Microsurgery SBU generated the least growth, increasing its revenue only slightly, to EUR 206.7 million (previous year: EUR 204.5 million). On an adjusted basis, the surgical microscopes and visualization solutions business would have recorded a decline of 4.1 percent. Revenue in Japan, in particular, which is of special significance for this business unit, declined compared with a strong figure the previous year.
Revenue by region
The distribution of revenue across the regions in the first nine months of the financial year reflects the general growth trend and the fluctuation of currencies:
In the EMEA region (Europe, Middle East and Africa), revenue increased by 8.5 percent, to EUR 261.9 million. Significant growth was achieved in Germany and the United Kingdom, in particular. In the Americas region, the recovery of the U.S. market and the strength of the U.S. dollar led to an 18.8 percent jump in revenue; adjusted for currency effects, however, this growth would have amounted to just 3.7 percent. In the APAC (Asia/Pacific) region, which reported an increase in revenue of 6.4 percent, to EUR 231.6 million, high growth rates from China and India were offset by a declining trend in the Japanese market.
Based on the very solid development overall and a product range with strong unique selling points, the Company is aiming to secure its competitive strength in the long term through process and cost optimization measures and targeted investments in new areas of growth. The projections for the financial year remain the same: “We are looking ahead with cautious optimism and are aiming for an EBIT margin – adjusted for strategic upfront R&D investments – of between 13 and 15 percent. Our projected revenue target for the current financial year is still set at a corridor of EUR 960 million to EUR 1,000 million,” says Ludwin Monz.
Revenue by strategic business unit
| Figures in EUR ‘000 | 9 Months 2013/14 | 9 Months 2014/15 | Change from previous year | Change from previous year (adjusted for currency effects) |
| Ophthalmic Systems | 248,939 | 283,542 | + 13.9% | + 5.7% |
| Surgical Ophthalmology | 220,308 | 258,506 | + 17.3% | + 14.2% |
| Microsurgery | 204,476 | 206,653 | + 1.1% | – 4.1% |
Revenue by region
| Figures in EUR ‘000 | 9 Months 2013/14 | 9 Months 2014/15 | Change from previous year | Change from previous year (adjusted for currency effects) |
| EMEA | 241,391 | 261,932 | + 8.5% | + 8.0% |
| Americas | 214,745 | 255,153 | +18.8% | +3.7% |
| APAC | 217,587 | 231,616 | + 6.4% | +4.5% |
Press contact:
Jann Gerrit Ohlendorf, Director Corporate Communications, Carl Zeiss Meditec AG
Phone +49 (0)3641 220-331, E-Mail: [email protected]
Investors contact:
Sebastian Frericks, Director Investor Relations, Carl Zeiss Meditec AG
Phone +49 (0)3641 220-116, E-Mail: [email protected]
2015-08-07 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
| Language: | English |
| Company: | Carl Zeiss Meditec AG |
| Göschwitzer Str. 51-52 | |
| 07745 Jena | |
| Germany | |
| Phone: | +49 (0)3641 220-0 |
| Fax: | +49 (0)3641 220-112 |
| E-mail: | [email protected],[email protected] |
| Internet: | www.meditec.zeiss.de |
| ISIN: | DE0005313704 |
| WKN: | 531370 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart |
| End of News | DGAP News-Service |
| - - - |
| 384599 2015-08-07 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.